• Loss of brain function after stroke or concussion mainly due to secondary death of brain cells
• NYX-104 confirmed as inhibitor of this secondary process in animals
• NYX-104 being developed as a first-in-class neuroprotection drug to minimise loss of brain function following stroke, concussion and head trauma
• Significant opportunity to reduce rehabilitation times following stroke and head and spinal injury
• NYX-104 opportunity to be explained by UNSW scientists at EGM on 6 November 2017.
Sydney, 3 November 2017: Noxopharm announced on 16 March 2017 that it had entered into a collaboration with UNSW Sydney to develop a drug designed to assist patients recovering from traumatic brain injury due to stroke, concussion, head trauma or severe epileptic seizure. The aim was to develop a drug to be given to a patient post-injury to limit knock-on, secondary brain damage and resulting loss of brain function, thereby increasing survival and reducing rehabilitation time and costs.
For further information please download PDF attached:
Download this document
